Complement C1 inhibitor protein - Shire

Drug Profile

Complement C1 inhibitor protein - Shire

Alternative Names: C1 esterase inhibitor - Baxter Healthcare; C1 esterase inhibitor - Hyland Immuno; C1 esterase inhibitor - Shire; C1 Inattivatore Umano; C1 inhibitor - Hyland Immuno; C1 inhibitor - Shire; Complement C1 esterase inhibitor - Baxter Healthcare; Complement C1 esterase inhibitor - Hyland Immuno; Complement C1 esterase inhibitor - Shire

Latest Information Update: 15 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter International
  • Developer Baxalta; Hyland Immuno
  • Class Complement C1 inactivator proteins; Vascular disorder therapies
  • Mechanism of Action Complement C1r inhibitors; Complement C1s inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angioedema
  • Discontinued Pancreatic disorders; Transplant rejection

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 16 Feb 2016 Biomarkers information updated
  • 19 Apr 2002 No development reported - Clinical-Phase-Unknown for Angioneurotic oedema in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top